Adjunctive Fludrocortisone in Septic Shock
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 32 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Fludrocortisone 100 mcg daily
- Placebo
- Record updated
- 2 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- suspected or confirmed adult sepsis as defined by ≥ 2 increase in Sequential Organ Failure Assessment (SOFA) score due to infection
- ≥0.25 μg/kg/min of noradrenaline infusion or vasoactive-inotropic score (VIS) ≥25 to maintain mean arterial pressure (MAP) ≥65 mmHg for at least 1 hour
- onset of septic shock within 24 hours
- shock due to infection with no other proven or apparent cause
- hypoperfusion defined as arterial or venous lactate concentration >2.0 mmol/L
- mechanical ventilation
Who cannot take part
- limitation of therapy
- receiving immunomodulatory agents including hydrocortisone > 300mg/day
- enteral medication cannot be administered
- an underlying disease process with a life expectancy of less than 90 days
- prescribed fludrocortisone for other medical condition
- fludrocortisone cannot be administered within 24 hours of onset of septic shock
- death is deemed imminent or inevitable by treating clinicians
- pregnancy (confirmed or suspected)
- contraindication to hydrocortisone or fludrocortisone
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a life-threatening condition caused by the body's dysregulated response to an infection. While corticosteroids are known to help stabilize blood pressure in septic shock, their ability to reduce mortality is still debated. Recent analyses suggest that combining fludrocortisone with hydrocortisone may be more effective at saving lives than hydrocortisone alone.
Read full original descriptionShow less
To test this hypothesis, a large, definitive international trial is needed. However, this research proposal is for a smaller pilot study (Phase II) involving 32 critically ill patients. The primary goal of this pilot is to determine the feasibility of conducting the subsequent large-scale trial that would compare hydrocortisone alone against the combination therapy and potentially change medical practice.
The 2 groups in the trial
- FludrocortisoneTreatment being tested
Treatment: Fludrocortisone 100 mcg daily
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adjunctive Fludrocortisone in Septic Shock: a Multicenter, Double-blind, Randomized, Placebo-controlled Pilot Trial (AFLUDROS-1)
- Record updated
- 2 June 2026